Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in Diffuse Cutaneous Systemic Sclerosis (Phase 2, Randomized, Double-blind, Placebo-controlled)
2020-005764-62Phase 2Active
- Sponsor
- Horizon Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in systemic sclerosis (SSc) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in FVC % predicted from Baseline to Week 52. Started Apr 2021; status: active.
02
Drugs
fipaxalparant
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2020-005764-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005764-62.